The effect of rosuvastatin treatment on the mean platelet volume in patients with uncontrolled primary dyslipidemia with hypolipidemic diet treatment

References

• Benzaquen LR, Yu H, Rifai N. High sensitivity C-reactive protein: An emerging role in cardiovascular risk assessment. Crit Rev Clin Lab Sci 2002; 39: 459–497
   PubMed Web of Science ®Google Scholar
• Tsiara S, Elisaf M, Jagroop IA, Mikhailidis DP. Platelets as predictors of vascular risk: Is there a practical index of platelet activity?. Clin Appl Thromb Hemost 2003; 9: 177–190
   PubMed Web of Science ®Google Scholar
• Broadley AJ, Gapper P, Schmitt M, Frenneaux MP. Supine rest reduces platelet activation and aggregation. Platelets 2003; 14: 3–7
   PubMed Web of Science ®Google Scholar
• Bancroft AJ, Abel EW, Mclaren M, Belch JJ. Mean platelet volume is a useful parameter: A reproducible routine method using a modified Coulter thrombocytomer. Platelets 2000; 11: 379–387
   PubMed Web of Science ®Google Scholar
• Allen RD, Zacharski LR, Widirstky ST, Rosenstein R, Zaitlin LM, Burgess DR. Transformation and motility of human platelets: Details of the shape change and release reaction observed by optical and electron microscopy. J Cell Biol 1979; 83: 126–142
   PubMed Web of Science ®Google Scholar
• Greisenegger S, Endler G, Hsieh K, Tentschert S, Mannhalter C, Lalouschek W. Is elevated mean platelet volume associated with a worse outcome in patients with acute ischemic cerebrovascular events?. Stroke 2004; 35: 1688–1691
   PubMed Web of Science ®Google Scholar
• Endler G, Klimesch A, Sunder-Plassmann H, Schillinger M, Exner M, Mannhalter C, Jordanova N, Christ G, Thalhammer R, Huber K, Sunder-Plassmann R. Mean platelet volume is an independent risk factor for myocardial infarction but not for coronary artery disease. Br J Haematol 2002; 117: 399–404
   PubMed Web of Science ®Google Scholar
• Martin JF, Bath PM, Burr ML. Influence of platelet size on outcome after myocardial infarction. Lancet 1991; 338: 1409–1411
   PubMed Web of Science ®Google Scholar
• Tschoepe D, Esser J, Schwippert B, Rosen P, Kehrel B, Niewuenhuis HK, Kehrel B, Gries FA. Large platelets circulate in an activated state in diabetes mellitus. Semin Thromb Hemost 1991; 17: 433–438
   PubMed Web of Science ®Google Scholar
• Bath PM, Butterworth RJ. Platelet size: measurement, physiology and vascular disease. Blood Coagul Fibrinolysis 1996; 7: 157–161
   PubMed Web of Science ®Google Scholar
• Kario K, Matsuo T, Nakao K. Cigarette smoking increases the mean platelet volume in elderly patients with risk factors for atherosclerosis. Clin Lab Haematol 1992; 14: 281–287
   PubMedGoogle Scholar
• Bath PM, Missouris CG, Buckenham T, MacGregor GA. Increased platelet volume and platelet mass in patients with atherosclerotic renal artery stenosis. Clin Sci (Lond) 1994; 87: 253–257
   PubMed Web of Science ®Google Scholar
• Culhane NS, Lettieri SL, Skae JR. Rosuvastatin for the treatment of hypercholesterolemia. Pharmacotherapy 2005; 25: 990–1000
   PubMedGoogle Scholar
• Lacoste L, Lam JY, Hung K, Letchacovski G, Solymoss CB, Waters D. Hyperlipidemia and coronary disease: correction of the increased thrombogenic potential with cholesterol reduction. Circulation 1995; 92: 3172–3177
   PubMed Web of Science ®Google Scholar
• Aviram M, Hussein O, Rosenblatt M, Schlezinger S, Hayek T, Keidar S. Interactions of platelets, macrophages, and lipoproteins in hypercholesterolemia: Antiatherogenic effects of HMG-CoA reductase inhibitor therapy. J Cardiovasc Pharmacol 1998; 31: 39–45
   PubMed Web of Science ®Google Scholar
• Dangas G, Smith DA, Badimon JJ, Unger AH, Shao JH, Meraj P, Cohen AM, Levine D, Fallon JT, Ambrose JA. Gender differences in blood thrombogenicity in hyperlipidemic patients and response to pravastatin. Am J Cardiol 1999; 84: 639–643
   PubMedGoogle Scholar
• Tsakiris DA, Keller U, Zulewski H, Miserez AR, Wolf F, Marbet GA. Simvastatin reduces activation of normal platelets by LDL isolated from patients with familial hypercholesterolaemia and familial defective apolipoprotein. B Eur J Clin Pharmacol 1997; 53: 277–279
   PubMedGoogle Scholar
• Szczeklik A, Musial J, Undas A, Gajewski P, Gora P, Swadzba J, Jankowski M. Inhibition of thrombin generation by simvastatin and lack of additive effects of aspirin in patients with marked hypercholesterolemia. J Am Coll Cardiol 1999; 33: 1286–1293
   PubMed Web of Science ®Google Scholar
• Tannous M, Cheung R, Vignini A, Mutus B. Atorvastatin increases ecNOS levels in human platelets of hyperlipidemic subjects. Thromb Haemost 1999; 82: 1390–1394
   PubMed Web of Science ®Google Scholar
• Pitt B, Waters D, Brown WV, van BA, Schwartz L, Title LM, Eisenberg D, Shurzinske L, McCormick LS. Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease. N Engl J Med 1999; 341: 70–76
   PubMed Web of Science ®Google Scholar
• Broijersen A, Eriksson M, Larsson PT, Beck O, Berglund L, Angelin B, Hjemdahl P. Effects of selective LDL-apheresis and pravastatin therapy on platelet function in familial hypercholesterolaemia. Eur J Clin Invest 1994; 24: 488–98
   PubMed Web of Science ®Google Scholar
• Krysiak R, Okopien B, Herman Z. Effects of HMG-Coa reductase inhibitors on coagulation and fibrinolysis processes. Drugs 2003; 63: 1821–1854
   PubMed Web of Science ®Google Scholar
• Liao JK, Laufs U. Pleiotropic effects of statins. Annu Rev Pharmacol Toxicol 2005; 45: 89–118
   PubMed Web of Science ®Google Scholar
• Undas A, Brummel-Ziedins KE, Mann KG. Statins and blood coagulation. Arterioscler Thromb Vasc Biol 2005; 25: 287–294
   PubMed Web of Science ®Google Scholar
• Aikawa M, Rabkin E, Sugiyama S, Voglic SJ, Fukumoto Y, Furukawa Y, Shiomi M, Schoen FJ, Libby P. An HMG-CoA reductase inhibitor, cerivastatin, suppresses growth of macrophages expressing matrix metalloproteinases and tissue factor in vivo and in vitro. Circulation 2001; 103: 276–283
   PubMed Web of Science ®Google Scholar
• Kadıköylu G, Yukselen V, Yavasoglu I, Bolaman Z. Hemostatic effects of atorvastatin versus simvastatin. Ann Pharmacother 2003; 37: 478–484
   PubMed Web of Science ®Google Scholar
• Shi J, Wang J, Zheng H, Ling W, Joseph J, Li D, Mehta JL, Ponnappan U, Lin P, Fink LM, Hauer-Jensen M. Statins increase thrombomodulin expression and function in human endothelial cells by a nitric oxide-dependent mechanism and counteract tumor necrosis factor alpha-induced thrombomodulin downregulation. Blood Coagul Fibrinolysis 2003; 14: 575–585
   PubMedGoogle Scholar
• Parson RB, Price GC, Farrant JK, Subramaniam D, Adeagbo-Sheikh J, Austen BM. Statins inhibit the dimerization of beta-secretase via both isoprenoid-and cholesterol mediated mechanisms. Biochem J 2006; 399: 205–214
   PubMedGoogle Scholar
• Beyan C, Kaptan K, Ifran A. Mean platelet volume is not correlated with body mass index in patients with microcytic anaemia. Int J Clin Pract 2006; 60: 871–872
   PubMedGoogle Scholar
• Wynn RF, Davies SV, Williams K, Trevett DG. The effects of time from venepuncture and choice of anticoagulant on mean platelet volume estimations. Clin Lab Haematol 1995; 17: 173–176
   PubMedGoogle Scholar
• Trowbridge EA, Reardon DM, Hutchinson D, Pickering C. The routine measurement of platelet volume: A comparison of light-scattering and aperture-impedance technologies. Clin Phys Physiol Meas 1985; 6: 221–238
   PubMedGoogle Scholar